Fredag 3 Januari | 05:50:43 Europe / Stockholm
Svenska | English

SenzaGen

Bifogade filer

Kursutveckling under dagen för detta pressmeddelande (SEK).

Likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2025-02-13 08:30 Bokslutskommuniké 2024
2024-11-08 - Kvartalsrapport 2024-Q3
2024-08-22 - Kvartalsrapport 2024-Q2
2024-05-16 - X-dag ordinarie utdelning SENZA 0.00 SEK
2024-05-15 - Årsstämma
2024-05-15 - Kvartalsrapport 2024-Q1
2024-02-14 - Bokslutskommuniké 2023
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-05 - X-dag ordinarie utdelning SENZA 0.00 SEK
2023-05-04 - Årsstämma
2023-02-16 - Bokslutskommuniké 2022
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-06 - X-dag ordinarie utdelning SENZA 0.00 SEK
2022-05-05 - Årsstämma
2022-02-11 - Bokslutskommuniké 2021
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-06 - X-dag ordinarie utdelning SENZA 0.00 SEK
2021-05-05 - Årsstämma
2021-02-18 - Bokslutskommuniké 2020
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-11 - X-dag ordinarie utdelning SENZA 0.00 SEK
2020-05-08 - Årsstämma
2020-02-13 - Bokslutskommuniké 2019
2019-12-18 - Extra Bolagsstämma 2019
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-16 - X-dag ordinarie utdelning SENZA 0.00 SEK
2019-05-15 - Årsstämma
2019-02-14 - Bokslutskommuniké 2018
2018-08-22 - Kvartalsrapport 2018-Q2
2018-05-09 - X-dag ordinarie utdelning SENZA 0.00 SEK
2018-05-08 - Årsstämma
2018-02-14 - Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Senzagen är verksamt inom medicinteknik. Bolaget utvecklar och genomför genomiska in vitro-tester, vilket innebär att olika kemikaliers toxikologiska förmåga inte testas på djur utan istället i provrör. Bolaget har utvecklat en teknologisk plattform som används för att studera substansers påverkan producerat av aktörer inom läkemedel, kosmetika- och kemikalieindustrin. Forskning och utveckling sker från huvudkontoret i Lund.
SenzaGen's 2020 Half-Year Report: Sales doubled in first half year
2020-08-20 08:30:00

Message from the CEO
”Despite operating in a time when the ordering and purchasing processes of our customers have been significantly influenced by COVID-19, our sales increased in the first six months of 2020 to SEK 3.8 million, representing a more than double year-on-year increase and one million higher than our entire 2019 sales. With a focused sales organization and more potential customers evaluating our tests, we are in a great position to continue developing as a commercial enterprise despite the current external challenges. I believe that we have passed the test of transitioning to the "new normal" with flying colors and that we will be able to keep up the same fast pace when working on our strategic initiatives in the fall.”

Axel Sjöblad, CEO

Half year 1 January–30 June

  • Net sales totaled SEK 3.8 (1.7) million.
  • The operating loss was SEK -12.9 (-15.2) million.
  • Earnings per share were SEK -0.60 (-0.97).
  • Cash and cash equivalents at 30 June amounted to SEK 101.5 (41.9) million.

Significant events during the first half year

  • A new global customer ordered tests for a cumulative value of SEK 1.2 million.
  • SenzaGen received an order worth SEK 0.5 million from a world-leading raw material supplier.
  • SenzaGen received GLP approval.
  • SenzaGen and XCellR8 expanded their collaboration to offer GARD®skin Animal Product-Free.
  • SenzaGen and US Research Institute for Fragrance Materials (RIFM) signed a collaboration agreement to develop next-generation tests for photosensitization.

Significant events after the end of the period

  • SenzaGen signed a distribution agreement with Danske Teknologisk Institut (DTI) in Denmark.


Conference call
SenzaGen is pleased to invite press and investors to a conference call on Thursday, August 20 at 9:30 CEST where CEO Axel Sjöblad will comment on SenzaGen’s 2020 half-year results. The conference call, which will be held in English, will begin with a presentation of the report followed by a Q&A session.

Phone number for conference call
To participate in the conference call, use the dial-in numbers below.

SE: +46850558351
FR: +33170750737
DE: +4969222239167
CH: +41225675632
NE: +31107129162
UK: +443333009269

Web link
https://tv.streamfabriken.com/senzagen-q2-2020

Contacts

Axel Sjöblad, CEO, SenzaGen AB
Email: axel.sjoblad@senzagen.com| Mobile: +46 705-35 93 51

Marianne Olsson, VP Finance
Email: marianne.olsson@senzagen.com| Mobile: +46 706-36 73 18

About us

SenzaGen is a Swedish biotech company that provides state-of-the-art animal-free tests for assessing whether a chemical causes allergies. The GARD® test method combines genomic data from human cells with machine learning for a unique capability to identify and analyze whether a chemical causes allergic reactions on the skin or in the respiratory tract. With excellent predictivity, GARD® meets needs in several industries and helps companies develop, produce and deliver safer, ethical and more sustainable products. GARD® tests are performed in SenzaGen’s GLP-approved lab and by select partners in Europe and the US. SenzaGen has its headquarters in Lund, Sweden and a subsidiary in the US. For more information, please visit: www.senzagen.com. 
 
SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA), and FNCA Sweden AB, +46(0)8-528 00 399, info@fnca.se, is the company’s Certified Adviser. 

This information is information that SenzaGen is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2020-08-20 08:30 CEST.

Attachments

SenzaGen AB (publ) 2020 Half Year Report

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden